Study in Patients With Relapsed/Refractory Primary Mediastinal Lymphoma Treated With Pembrolizumab or Nivolumab in Combination With Brentuximab Vedotin in a Real-life Context
Clinical trial NCT06781450 · RECRUITING
Trial details
- NCT number
- NCT06781450
- Sponsor
- IRCCS Azienda Ospedaliero-Universitaria di Bologna
- Status
- RECRUITING
- Study type
- OBSERVATIONAL
- Start date
- 2022-04-23
- Primary completion
- 2025-12-01
- Enrollment
- 50
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.